Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec;14(1):2432726.
doi: 10.1080/2162402X.2024.2432726. Epub 2024 Dec 18.

Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference

Pierre-Antoine Laurent  1   2 , Fabrice André  3   4   5 , Alexandre Bobard  6 , Desiree Deandreis  7 , Sandra Demaria  8   9   10 , Stephane Depil  11   12 , Stefan B Eichmüller  13 , Cristian Fernandez-Palomo  14 , Floris Foijer  15 , Lorenzo Galluzzi  8   10   16 , Jérôme Galon  17   18 , Matthias Guckenberger  19 , Kevin J Harrington  20 , Fernanda G Herrera  21   22   23 , Peter E Huber  24   25 , Antoine Italiano  26   27   28 , Sana D Karam  29   30 , Guido Kroemer  31   32   33   34 , Philippe Lambin  35   36 , Carola Leuschner  37 , Alberto Mantovani  38   39 , Etienne Meylan  40   41   42 , Michele Mondini  2 , Mikael J Pittet  23   43   44   45   46 , Jean-Pierre Pouget  47 , Jordi Remon  3 , Claus S Sørensen  48 , Christos Sotiriou  49 , Claire Vanpouille-Box  8   10 , Ralph R Weichselbaum  50 , James W Welsh  37 , Laurence Zitvogel  51   52   53   54 , Silvia C Formenti  8   10 , Eric Deutsch  1   2   54   55
Affiliations

Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference

Pierre-Antoine Laurent et al. Oncoimmunology. 2025 Dec.

Abstract

Over the last decade, the annual Immunorad Conference, held under the joint auspicies of Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) has aimed at exploring the latest advancements in the fields of tumor immunology and radiotherapy-immunotherapy combinations for the treatment of cancer. Gathering medical oncologists, radiation oncologists, physicians and researchers with esteemed expertise in these fields, the Immunorad Conference bridges the gap between preclinical outcomes and clinical opportunities. Thus, it paves a promising way toward optimizing radiotherapy-immunotherapy combinations and, from a broader perspective, improving therapeutic strategies for patients with cancer. Herein, we report on the topics developed by key-opinion leaders during the 7th Immunorad Conference held in Paris-Les Cordeliers (France) from September 27th to 29th 2023, and set the stage for the 8th edition of Immunorad which will be held at Weill Cornell Medical College (New-York, USA) in October 2024.

Keywords: Cancer; FLASH radiotherapy; T cells; immune checkpoint; immunorad; immunotherapy; low-dose radiotherapy; lymph-node sparing; radiotherapy; tumor-associated macrophages.

PubMed Disclaimer

Conflict of interest statement

F.A. reports travel/accommodation/expenses from AstraZeneca, GlaxoSmithKline, Novartis, Pfizer, and Roche, and his institution has received research funding from AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer, and Roche. He received Consultant/Advisory fees from Amgen, Astellas, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, MSD, Novartis, Pfizer, Roche, Sanofi, Orion. S.D. is the founder and chairman of ErVimmune. L.G. is/ has been holding research contracts with Lytix Biopharma, Promontory and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. He is an Editorial Board Member for OncoImmunology and was not involved in the editorial review or the decision to publish this article. J.G. is a co-founder of HalioDx. K.H. reports Advisory Board/Steering Committee Membership: ALX Pharma; AstraZeneca; Bicara; BMS; Boehringer-Ingelheim; Exelixis; GSK; Merck-Serono; Merus; MSD; Replimune, and Research Grants: AstraZeneca; Boehringer-Ingelheim; Replimune. A.I. has received research grant from Bayer, Bristol Myers Squibb, Roche, Novartis, Chugai, Merck, AstraZeneca, Merck Sharp & Dohme and IPSEN and is an advisory board member for Bayer, Bristol Myers Squibb, Roche, Novartis, Chugai, Merck, AstraZeneca, Merck Sharp & Dohme, IPSEN and Parthenon. S.K. receives also receives preclinical research funding from Roche, which supported some of the work presented in this manuscript. G.K. is an Editorial Board Member for OncoImmunology and was not involved in the editorial review or the decision to publish this article. J.R. is an Editorial Board Member/Editor-in-Chief/Associate Editor/Guest Editor for JCO, JTO, JTO, CCR, Lung Cancer and was not involved in the editorial review or the decision to publish this article. R.R.W. has stock and other ownership interests with Boost Therapeutics, Immvira LLC, Reflexion Pharmaceuticals, Coordination Pharmaceuticals Inc., Magi Therapeutics, Oncosenescence, Aqualung Therapeutics Corporation, Cyntegron and PersonaDX. He has served in a consulting or advisory role for Aettis Inc., AstraZeneca, Coordination Pharmaceuticals, Genus, Merck Serono S.A., Nano Proteagen, NKGen Biotech, Shuttle Pharmaceuticals, Highlight Therapeutics, S.L., Aqualung Therapeutics Corporation. He has research grants with Varian and Regeneron. J.W.W. reports grant funding from Alkermes, Nanobiotix, Merck, GlaxoSmithKline, Checkmate Pharmaceuticals, Varian, Bristol Myers Squibb, Reflexion, Artidis, Takeda, Gilead, HotSpot Therapeutics, and Kiromic; travel grants from Ventana, Aileron, Nanobiotix, Varian, and Reflexion; advisory fees from Alpine Immune Sciences, Reflexion, Aileron, Molecular Match, OncoResponse, Checkmate Pharmaceuticals, and Marvu Pharmaceuticals; a consultant role for Alpine Immune Sciences, Reflexion, Merck, Molecular Match, OncoResponse, Checkmate Pharmaceuticals, Marvu Pharmaceuticals, Incyte, Nanobiotix, Aileron, GI Innovation, Legion Healthcare, Roche, and Ventana Medical Systems; and stock options in Alpine Immune Sciences, Reflexion, Legion Healthcare, Molecular Match, OncoResponse, and Nanorobotix. L.Z. has been an editor-in-chief of Oncoimmunology from 2011 to 2021 and has not been involved in the editorial review or the decision to publish this article. L.Z. is a founder of everIMMUNE, a biotech company involved in the development of live biotherapeutics including Akkermansia spp. in the arena of oncoimmunology. As such LZ is the SAB President of everIMMUNE and receives a financial compensation and is supported via a research contract. L.Z. is supported by Pileje to work on prebiotics in IO. S.C.F. has consultant: Bayer, Bristol Myers Squibb, Varian, ViewRay, Accuray, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, Astra Zeneca, MedImmune, Merck US, EMD Serono/Merck, Genentech/ROCHE, Boehringer Ingelheim, Nanobiotix and Grant/Research support from: Bristol Myers Squibb, Varian, Regeneron, Merck, Celldex. All other authors have no conflict of interest to declare. E.D. reports grants and personal fees from Roche Genentech; grants from Servier; grants from AstraZeneca; grants and personal fees from Merck-Serono; grants from BMS; and grants from MSD outside the submitted work. All other authors have no conflict of interest to declare.

Disclosures from the last 36 months within and outside the submitted work: PL: none related to the current manuscript; outside of current manuscript: grants/sponsored research agreements from Radiomics SA, Convert Pharmaceuticals SA and LivingMed Biotech srl. He received a presenter fee and/or reimbursement of travel costs/consultancy fee (in cash or in kind) from Astra Zeneca, BHV srl & Roche. PL has/had minority shares in the companies Radiomics SA, Convert pharmaceuticals SA, Comunicare SA, LivingMed Biotech srl and Bactam srl. PL is co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248 and PCT/NL2014/050728), licensed to Radiomics SA; one issued patent on mtDNA (PCT/EP2014/059089), licensed to ptTheragnostic/DNAmito; one granted patent on LSRT (PCT/ P126537PC00, US patent No. 12,102,842), licensed to Varian; one issued patent on Radiomic signature of hypoxia (U.S. Patent 11,972,867), licensed to a commercial entity; one issued patent on Prodrugs (WO2019EP64112) without royalties; one non-issued, non-licensed patents on Deep Learning-Radiomics (N2024889) and three non-patented inventions (softwares) licensed to ptTheragnostic/DNAmito, Radiomics SA and Health Innovation Ventures). PL confirms that none of the above entities were involved in the preparation of this paper.

Figures

Figure 1.
Figure 1.
Overview of thematic discussions on optimizing radiotherapy-immunotherapy combination strategies at the immunorad Conference.
Figure 2.
Figure 2.
Overview of the technological innovations in the field of precision oncology and personalized medicine presented and discussed at immunorad Conference.
Figure 3.
Figure 3.
Summary of the advances presented at immunorad conference likely to change the paradigms of radiotherapy in the future.
See this image and copyright information in PMC

References

    1. Mantovani A, Allavena P, Marchesi F, Garlanda C.. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21(11):799–13. doi:10.1038/s41573-022-00520-5. - DOI - PMC - PubMed
    1. Bill R, Wirapati P, Messemaker M, Roh W, Zitti B, Duval F, Kiss M, Park JC, Saal TM, Hoelzl J, et al. CXCL9: SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. Science. 2023;381(6657):515–524. doi:10.1126/science.ade2292. - DOI - PMC - PubMed
    1. Zitvogel L, Casares N, Péquignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. Adv Immunol. 2004;84:131–179. doi:10.1016/S0065-2776(04)84004-5. - DOI - PubMed
    1. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31(1):51–72. doi:10.1146/annurev-immunol-032712-100008. - DOI - PubMed
    1. Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8(1):e000337. doi:10.1136/jitc-2019-000337. - DOI - PMC - PubMed

Publication types